Fulton Breakefield Broenniman LLC Bristol Myers Squibb CO Transaction History

Fulton Breakefield Broenniman LLC

$1.41 Billion
Q3 2024

A detailed history of Fulton Breakefield Broenniman LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Fulton Breakefield Broenniman LLC holds 4,469 shares of BMY stock, worth $254,017. This represents 0.02% of its overall portfolio holdings.

Number of Shares

4,469

Holding current value

$254,017

% of portfolio

0.02%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 16, 2024	BUY	$39.66 - $51.75 $177,240 - $231,270	4,469 New	4,469 $231,000
Q1 2024 Apr 29, 2024	SELL	$47.98 - $54.4 $287 - $326	-6 Reduced 0.13%	4,738 $256,000
Q4 2023 Feb 02, 2024	BUY	$48.48 - $57.85 $10,132 - $12,090	209 Added 4.61%	4,744 $243,000
Q3 2023 Oct 20, 2023	SELL	$57.89 - $64.73 $8,972 - $10,033	-155 Reduced 3.3%	4,535 $263,000
Q2 2023 Jul 19, 2023	SELL	$63.71 - $70.74 $1,783 - $1,980	-28 Reduced 0.59%	4,690 $299,000
Q1 2023 Apr 25, 2023	SELL	$65.71 - $74.53 $23,458 - $26,607	-357 Reduced 7.03%	4,718 $327,000
Q4 2022 Jan 31, 2023	BUY	$68.48 - $81.09 $20,544 - $24,327	300 Added 6.28%	5,075 $365,000
Q3 2022 Oct 17, 2022	SELL	$0.13 - $76.84 $3 - $1,844	-24 Reduced 0.5%	4,775 $339,000
Q2 2022 Jul 28, 2022	SELL	$72.62 - $79.98 $37,326 - $41,109	-514 Reduced 9.67%	4,799 $370,000
Q1 2022 Apr 27, 2022	BUY	$61.48 - $73.72 $25,698 - $30,814	418 Added 8.54%	5,313 $388,000
Q4 2021 Feb 07, 2022	BUY	$53.63 - $62.52 $74,545 - $86,902	1,390 Added 39.66%	4,895 $305,000
Q2 2021 Jul 27, 2021	BUY	$61.91 - $67.42 $61 - $67	1 Added 0.03%	3,505 $234,000
Q1 2021 Apr 09, 2021	BUY	$59.34 - $66.74 $207,927 - $233,856	3,504 New	3,504 $221,000
Q4 2020 Jan 14, 2021	SELL	$57.74 - $65.43 $215,774 - $244,511	-3,737 Closed	0 $0
Q3 2020 Oct 20, 2020	SELL	$57.43 - $63.64 $28,370 - $31,438	-494 Reduced 11.68%	3,737 $225,000
Q2 2020 Jul 10, 2020	BUY	$54.82 - $64.09 $231,943 - $271,164	4,231 New	4,231 $249,000
Q1 2020 Apr 10, 2020	SELL	$46.4 - $67.43 $154,790 - $224,946	-3,336 Closed	0 $0
Q4 2019 Jan 14, 2020	BUY	$49.21 - $64.19 $164,164 - $214,137	3,336 New	3,336 $214,000
Q2 2019 Jul 25, 2019	SELL	$44.62 - $49.34 $4.4 Million - $4.87 Million	-98,706 Closed	0 $0
Q1 2019 Apr 17, 2019	BUY	$45.12 - $53.8 $70,026 - $83,497	1,552 Added 1.6%	98,706 $4.71 Million
Q4 2018 Feb 05, 2019	SELL	$48.76 - $63.23 $90,254 - $117,038	-1,851 Reduced 1.87%	97,154 $5.05 Million
Q3 2018 Oct 24, 2018	SELL	$55.19 - $62.25 $26,822 - $30,253	-486 Reduced 0.49%	99,005 $6.15 Million
Q2 2018 Aug 02, 2018	BUY	$50.53 - $62.98 $74,026 - $92,265	1,465 Added 1.49%	99,491 $5.51 Million
Q1 2018 Apr 19, 2018	SELL	$59.92 - $68.98 $40,745 - $46,906	-680 Reduced 0.69%	98,026 $6.2 Million
Q4 2017 Jan 30, 2018	BUY	$59.94 - $65.35 $11,988 - $13,069	200 Added 0.2%	98,706 $6.05 Million
Q3 2017 Oct 13, 2017	BUY	$55.23 - $63.74 $5.44 Million - $6.28 Million	98,506	98,506 $6.28 Million

Others Institutions Holding BMY

# of Institutions

2,537

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $121B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fulton Breakefield Broenniman LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fulton Breakefield Broenniman LLC with notifications on news.

Account

Fulton Breakefield Broenniman LLC Bristol Myers Squibb CO Transaction History